Delcath Systems Inc (DCTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Delcath Systems Inc (DCTH) has a cash flow conversion efficiency ratio of 0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($857.00K) by net assets ($112.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DCTH net asset quality index to measure how much of total assets are equity-financed.
Delcath Systems Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Delcath Systems Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Delcath Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Delcath Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lesaka Technologies Inc
NASDAQ:LSAK
|
0.144x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
0.043x |
|
Autolus Therapeutics Ltd
NASDAQ:AUTL
|
-0.600x |
|
Somalogic Inc
NASDAQ:SLGC
|
-0.043x |
|
Titan Machinery Inc
NASDAQ:TITN
|
0.308x |
|
Atrium Mortgage Investment Corp
TO:AI
|
-0.048x |
|
Promate Electronic Co Ltd
TW:6189
|
0.045x |
Annual Cash Flow Conversion Efficiency for Delcath Systems Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Delcath Systems Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.22 Million | $22.52 Million | 0.202x | +174.50% |
| 2024-12-31 | $68.75 Million | $-18.68 Million | -0.272x | +86.28% |
| 2023-12-31 | $15.78 Million | $-31.25 Million | -1.981x | -146.51% |
| 2022-12-31 | $-5.86 Million | $-24.95 Million | 4.258x | +325.17% |
| 2021-12-31 | $11.95 Million | $-22.60 Million | -1.891x | -82.59% |
| 2020-12-31 | $22.08 Million | $-22.87 Million | -1.036x | -127.80% |
| 2019-12-31 | $-6.36 Million | $-23.69 Million | 3.726x | +277.88% |
| 2018-12-31 | $-14.94 Million | $-14.73 Million | 0.986x | +104.34% |
| 2017-12-31 | $678.00K | $-15.40 Million | -22.711x | -338.09% |
| 2016-12-31 | $-1.49 Million | $-14.21 Million | 9.539x | +599.66% |
| 2015-12-31 | $8.60 Million | $-16.42 Million | -1.909x | -122.74% |
| 2014-12-31 | $18.14 Million | $-15.55 Million | -0.857x | +24.35% |
| 2013-12-31 | $30.10 Million | $-34.10 Million | -1.133x | +54.67% |
| 2012-12-31 | $20.01 Million | $-50.01 Million | -2.499x | -74.57% |
| 2011-12-31 | $26.10 Million | $-37.37 Million | -1.432x | -72.88% |
| 2010-12-31 | $29.08 Million | $-24.08 Million | -0.828x | -88.06% |
| 2009-12-31 | $23.76 Million | $-10.46 Million | -0.440x | +33.15% |
| 2008-12-31 | $10.21 Million | $-6.72 Million | -0.659x | -94.31% |
| 2007-12-31 | $16.43 Million | $-5.57 Million | -0.339x | +70.19% |
| 2006-12-31 | $8.09 Million | $-9.20 Million | -1.137x | -374.44% |
| 2005-12-31 | $12.60 Million | $-3.02 Million | -0.240x | +44.79% |
| 2004-12-31 | $6.79 Million | $-2.95 Million | -0.434x | +55.57% |
| 2003-12-31 | $2.17 Million | $-2.12 Million | -0.977x | +10.20% |
| 2002-12-31 | $1.64 Million | $-1.78 Million | -1.088x | -55.01% |
| 2001-12-31 | $3.23 Million | $-2.27 Million | -0.702x | -852.96% |
| 2000-12-31 | $4.91 Million | $-361.26K | -0.074x | +96.69% |
| 1999-12-31 | $490.00K | $-1.09 Million | -2.224x | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more